Biotech Values

[DewDiligence]

(REGN)—NICE backs Eylea with restrictions:

http://www.pharmatimes.com/Article/15-02-20/NICE_backs_Bayer_s_Eylea_after_discount_deal.aspx

The cost-watchdog is backing Eylea (aflibercept) in people where the eye has a central retinal thickness of 400 micrometres or more at the start of treatment.

...The response from Bayer has been mixed. The company says it is pleased NICE has recognised the benefits of Eylea in this indication but is disappointed that a core group of patients diagnosed with early-stage DMO (central retinal thickness less than 400 micrometres) would be denied treatment until their disease has progressed “to a stage where permanent damage to the eye has already begun”.